Untreated hearing loss affects roughly 1.5 billion people globally and is now recognized as one of the most modifiable risk factors for cognitive decline and dementia — making the accessibility of hearing aids a genuinely consequential public health issue, not merely a quality-of-life convenience. The 2022 FDA authorization of over-the-counter (OTC) hearing aids for adults with mild to moderate hearing loss marked a structural shift in how amplification devices reach consumers, removing the traditional audiologist gatekeeping that historically added cost and time barriers.
This JAMA Insights piece examines how modern hearing aids work — using directional microphones, digital signal processing, and feedback suppression to selectively amplify speech frequencies — while acknowledging inherent limitations such as difficulty in noisy environments and occlusion effects. It contrasts prescription devices, which are professionally fitted using audiometric testing and offer greater customization for complex loss patterns, against OTC alternatives that rely on consumer self-assessment and app-based fitting. The piece addresses how each pathway serves different audiological profiles and the clinical thresholds that distinguish mild-to-moderate from more severe loss requiring specialist intervention.
What makes this clinically relevant beyond audiology is the accumulating evidence linking even mild untreated hearing loss to accelerated cognitive aging. The landmark ACHIEVE trial (2023) demonstrated that hearing intervention significantly slowed cognitive decline in older adults at higher dementia risk — a finding that elevates hearing aid uptake from an audiological question to a neurological one. The OTC pathway, while promising for access, introduces real limitations: self-fitting accuracy varies considerably among users, and individuals with asymmetric or high-frequency-specific loss may be poorly served without professional assessment. For the health-conscious adult population, the key implication is that choosing between OTC and prescription is not merely a cost decision — it is an audiological and potentially cognitive health decision that warrants informed deliberation rather than default convenience.
